These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 736748)

  • 1. Recent results of in vitro drug prediction in human tumour chemotherapy.
    Nissen E; Tanneberger S; Projan A; Morack G; Peek U
    Arch Geschwulstforsch; 1978; 48(7):667-72. PubMed ID: 736748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
    Orr JW; Orr P; Kern DH
    Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adjuvant chemotherapy in patients operated on for early ovarian carcinoma].
    Trimbos JB; van der Burg ME
    Ned Tijdschr Geneeskd; 2004 May; 148(18):874-8. PubMed ID: 15152388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer.
    d'Amato TA; Landreneau RJ; McKenna RJ; Santos RS; Parker RJ
    Ann Thorac Surg; 2006 Feb; 81(2):440-6; discussion 446-7. PubMed ID: 16427828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Update of human tumor clonogenic assay in carcinoma of the lung].
    Kanzawa F
    Gan To Kagaku Ryoho; 1985 Aug; 12(8):1552-9. PubMed ID: 2992395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacotherapy in ovarian carcinoma].
    Pfisterer J; Du Bois A
    MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of the human tumor stem cell assay to new drug evaluation and screening.
    Salmon SE
    Prog Clin Biol Res; 1980; 48():291-312. PubMed ID: 7193873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A; Lück HJ; Meerpohl HG
    Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early-stage NSCLC: the role of radiotherapy and systemic therapy.
    Bunn PA
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S31-40. PubMed ID: 19780244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy testing for human ovarian cancer using in vitro colony assay].
    Inoue K
    Gan To Kagaku Ryoho; 1985 Aug; 12(8):1593-8. PubMed ID: 2411225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
    O'Meara AT; Sevin BU
    Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
    Tuxen MK; Sölétormos G; Dombernowsky P
    Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of high-dose chemotherapy in solid tumours.
    Nieboer P; de Vries EG; Mulder NH; van der Graaf WT
    Cancer Treat Rev; 2005 May; 31(3):210-25. PubMed ID: 15944050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
    Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
    Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
    Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
    J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of tritiated nucleotide incorporation for prediction of sensitivity of tumors to cytostatic agents.
    Volm M
    Behring Inst Mitt; 1984 May; (74):273-84. PubMed ID: 6383325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.